CA

(redirected from Cancer Antigen)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia.
Related to Cancer Antigen: Cancer antigen 19-9, Cancer antigen 15-3

CA

The two-character ISO 3166 country code for CANADA.

CA

1. ISO 3166-1 alpha-2 code for Canada. This is the code used in international transactions to and from Canadian bank accounts.

2. ISO 3166-2 geocode for Canada. This is used as an international standard for shipping to Canada. Each province and territory has its own code with the prefix "CA." For example, the code for the Territory of Nunavut is ISO 3166-2:CA-NU.
Mentioned in ?
References in periodicals archive ?
In parallel, we will undertake detailed pre-clinical comparisons of 5T4 to other leading prostate cancer antigens, including five newly identified prostate-specific antigens, using a well-characterised murine prostate tumour model, exploiting new technologies for maximising CD8+ T cell induction with viral vectors.
This meant that the immune system 'self-selected' the cancer antigens to respond to and did not react against other healthy parts of the body.
The XPRESIDENTA discovery platform is to date the only known high-throughput research technology to directly identify, quantify, and prioritize cancer antigens recognized by T lymphocytes (type of white blood cell) based on the ability of the immune system to detect them.
A significant body of literature reports the presence of autoantibodies against cancer antigens in the peripheral circulation of cancer patients--shown to be true in lung, breast, cervical, and colorectal cancers, among others.
chief executive officer of CureVac, said, "We have shown that RNActive vaccines are safe and induce balanced humoral and cellular immune responses against multiple cancer antigens in what was a first-of-its-kind study of an mRNA vaccine.
It includes high target levels of cancer antigens and ferritin, plus a very low level of PSA.
Ovarian cancer remains an unmet medical need, and we believe that our approach of targeting both specific ovarian cancer antigens and cancer stem cells may offer a meaningful therapeutic benefit to patients with this disease.
OncoTherapy Science will employ its technology for identification of the cancer antigens and generation of Mabs against those antigens, and BioWa will apply its POTELLIGENT(TM) technology to the Mabs for the enhancement of antibody-dependent cellular cytotoxicity (ADCC).
We have filed an Investigational New Drug (IND) application for ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells at the end of 2012.
We are on track to file an Investigational New Drug (IND) application for ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells at the end of 2012.
ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell vaccine targeting CD133; ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer killing T-cells.